Skyrizi Subcutaneous (risankizumab-rzaa) — Cigna

Initial criteria

• age ≥ 18 years
• Patient meets ONE of the following: has tried at least one traditional systemic agent for psoriasis (e.g., methotrexate, cyclosporine, acitretin) for at least 3 months, unless intolerant; OR has contraindication to methotrexate
• Medication is prescribed by or in consultation with a dermatologist

Reauthorization criteria

• Patient has been established on the requested drug for at least 3 months
• Patient experienced beneficial clinical response, defined as improvement from baseline in at least one of: estimated body surface area, erythema, induration/thickness, and/or scale of areas affected by psoriasis

Approval duration

initial 3 months; reauth 1 year